368870-03-5 Usage
General Description
4-(1H-Pyrazol-1-yl)benzylamine is a chemical compound with the formula C10H12N2. 4-(1H-PYRAZOL-1-YL)BENZYLAMINE belongs to the class of organic compounds known as phenylpyrazoles. It is used in various fields such as pharmaceuticals and agrochemicals. It has been studied for its potential to act as an anti-inflammatory and analgesic agent. Additionally, it exhibits insecticidal and acaricidal properties, making it a potential candidate for use in pesticide formulations. 4-(1H-Pyrazol-1-yl)benzylamine has also been investigated for its potential in the synthesis of new organic compounds with diverse biological activities. Overall, this compound has a wide range of potential applications and is of interest to researchers in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 368870-03-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,6,8,8,7 and 0 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 368870-03:
(8*3)+(7*6)+(6*8)+(5*8)+(4*7)+(3*0)+(2*0)+(1*3)=185
185 % 10 = 5
So 368870-03-5 is a valid CAS Registry Number.
InChI:InChI=1/C10H11N3/c11-8-9-2-4-10(5-3-9)13-7-1-6-12-13/h1-7H,8,11H2
368870-03-5Relevant articles and documents
PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS
-
, (2017/06/12)
The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: (I), where R1, R2, R3, R3', R4, R5, X1, X2, X3, X4, and n are described herein.
Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules
-
Paragraph 0127, (2013/05/22)
Compositions and methods which modulate diseases and disorders related to transducin β-like protein 1 (TBL1) activity, including but not limited to cancer, inflammation, and bone related diseases.
PYRIDYLAMINOACETIC ACID COMPOUND
-
Page/Page column 103, (2011/01/11)
The present invention provides a novel pyridylaminoacetic acid compound represented by the following formula (1): (wherein R1, R2, R3, Y and Z are as defined in the description and claims), or a pharmacologically acceptabl
